1h9o
From Proteopedia
| Line 4: | Line 4: | ||
|PDB= 1h9o |SIZE=350|CAPTION= <scene name='initialview01'>1h9o</scene>, resolution 1.79Å | |PDB= 1h9o |SIZE=350|CAPTION= <scene name='initialview01'>1h9o</scene>, resolution 1.79Å | ||
|SITE= <scene name='pdbsite=PTR:Ptr+Binding+Site'>PTR</scene> | |SITE= <scene name='pdbsite=PTR:Ptr+Binding+Site'>PTR</scene> | ||
| - | |LIGAND= | + | |LIGAND= <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene> |
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
| + | |DOMAIN= | ||
| + | |RELATEDENTRY= | ||
| + | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1h9o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1h9o OCA], [http://www.ebi.ac.uk/pdbsum/1h9o PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1h9o RCSB]</span> | ||
}} | }} | ||
| Line 14: | Line 17: | ||
==Overview== | ==Overview== | ||
Two cases of successful molecular replacement using NMR trial models are presented. One is the crystal structure of the Escherichia coli colicin immunity protein Im7; the other is a heretofore unreported crystal structure of a specific PDGF receptor-derived peptide complex of the carboxy-terminal SH2 domain from the p85alpha subunit of human phosphatidylinositol 3-OH kinase. In both cases, molecular replacement was non-trivial. Success was achieved using trial models that consisted of an ensemble of NMR structures from which the more flexible portions had been excised. Use of maximum-likelihood refinement proved critical to be able to refine the poor starting models. The challenges typical of the use of NMR trial models in molecular replacement are discussed. | Two cases of successful molecular replacement using NMR trial models are presented. One is the crystal structure of the Escherichia coli colicin immunity protein Im7; the other is a heretofore unreported crystal structure of a specific PDGF receptor-derived peptide complex of the carboxy-terminal SH2 domain from the p85alpha subunit of human phosphatidylinositol 3-OH kinase. In both cases, molecular replacement was non-trivial. Success was achieved using trial models that consisted of an ensemble of NMR structures from which the more flexible portions had been excised. Use of maximum-likelihood refinement proved critical to be able to refine the poor starting models. The challenges typical of the use of NMR trial models in molecular replacement are discussed. | ||
| - | |||
| - | ==Disease== | ||
| - | Known diseases associated with this structure: Myelomonocytic leukemia, chronic OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=173410 173410]], Myeloproliferative disorder with eosinophilia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=173410 173410]] | ||
==About this Structure== | ==About this Structure== | ||
| Line 38: | Line 38: | ||
[[Category: signal transduction]] | [[Category: signal transduction]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 21:00:41 2008'' |
Revision as of 18:00, 30 March 2008
| |||||||
| , resolution 1.79Å | |||||||
|---|---|---|---|---|---|---|---|
| Sites: | |||||||
| Ligands: | |||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
PHOSPHATIDYLINOSITOL 3-KINASE, P85-ALPHA SUBUNIT: C-TERMINAL SH2 DOMAIN COMPLEXED WITH A TYR751 PHOSPHOPEPTIDE FROM THE PDGF RECEPTOR, CRYSTAL STRUCTURE AT 1.79 A
Overview
Two cases of successful molecular replacement using NMR trial models are presented. One is the crystal structure of the Escherichia coli colicin immunity protein Im7; the other is a heretofore unreported crystal structure of a specific PDGF receptor-derived peptide complex of the carboxy-terminal SH2 domain from the p85alpha subunit of human phosphatidylinositol 3-OH kinase. In both cases, molecular replacement was non-trivial. Success was achieved using trial models that consisted of an ensemble of NMR structures from which the more flexible portions had been excised. Use of maximum-likelihood refinement proved critical to be able to refine the poor starting models. The challenges typical of the use of NMR trial models in molecular replacement are discussed.
About this Structure
1H9O is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
Reference
NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex., Pauptit RA, Dennis CA, Derbyshire DJ, Breeze AL, Weston SA, Rowsell S, Murshudov GN, Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1397-404. Epub, 2001 Sep 21. PMID:11567151
Page seeded by OCA on Sun Mar 30 21:00:41 2008
